Polycythemia vera

Polycythemia vera (PV) is an acquired myeloproliferative disorder characterized by an elevated absolute red blood cell mass caused by uncontrolled red blood cell production, frequently associated with uncontrolled white blood cell and platelet production.

Myelofibrosis

Replacement of bone marrow by fibrous tissue.


Total: 67

                       


(per page)
PMID (PMCID)
30602717
 FEMALE Middle Aged
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Hassankrishnamurthy S, Mody MD, Kota VK.
Am J Case Rep. 2019;20:10-14.
BACKGROUND Essential thrombocythemia (ET) is one of the BCR-ABL gene fusion negative chronic myeloproliferative disorders (MPDs), which also include polycythemia vera (PV), and myelofibrosis.
30639623
 MIXED_SAMPLE
Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S, Ledoux MP, Gravier S, Natarajan-Ame S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R.
Int J Infect Dis. 2019;80:134-136.
Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis.
30639623
 MIXED_SAMPLE
Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S, Ledoux MP, Gravier S, Natarajan-Ame S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R.
Int J Infect Dis. 2019;80:134-136.
Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
29685167
(5914053)
 MALE
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Habberstad AH, Tran HTT, Randen U, Spetalen S, Dybedal I, Tjonnfjord GE, Dahm AEA.
J Med Case Rep. 2018;12(1):105.
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
29685167
(5914053)
 MALE
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Habberstad AH, Tran HTT, Randen U, Spetalen S, Dybedal I, Tjonnfjord GE, Dahm AEA.
J Med Case Rep. 2018;12(1):105.
Hairy cell leukemia may mimic development to myelofibrosis in patients with polycythemia vera.
28660085
(5474248)
 OTHER
Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera.
Fei N, Sofka S.
Case Rep Hematol. 2017;2017:9091612.
Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera.
28781268
 FEMALE Middle Aged
Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.
Fujishima M, Fujishima N, Kitadate A, Guo Y, Watanabe A, Ubukawa K, Nara M, Yoshioka T, Kameoka Y, Takahashi N.
Rinsho Ketsueki. 2017;58(7):743-748.
One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.
28781268
 FEMALE Middle Aged
Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.
Fujishima M, Fujishima N, Kitadate A, Guo Y, Watanabe A, Ubukawa K, Nara M, Yoshioka T, Kameoka Y, Takahashi N.
Rinsho Ketsueki. 2017;58(7):743-748.
Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.
28674362
(5519475)
 MALE
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, Takeishi Y.
Intern Med. 2017;56(13):1705-1710.
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
28794380
(5635310)
 MIXED_SAMPLE Middle Aged
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M, Sueki Y, Kawashima I, Nakajima K, Mitsumori T, Kirito K.
Intern Med. 2017;56(17):2335-2338.
We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor.
26826764
 MALE Middle Aged
A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera.
Jeong JH, Ahn JY, Park PW, Seo YH, Seo JY, Lee JH, Kim KH.
Cancer Genet. 2016;209(3):112-6.
We report a novel t(11;14)(p13; q11.2) in a patient with myelofibrosis (MF) following polycythemia vera (PV).
26826764
 MALE Middle Aged
A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera.
Jeong JH, Ahn JY, Park PW, Seo YH, Seo JY, Lee JH, Kim KH.
Cancer Genet. 2016;209(3):112-6.
A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera.
27398203
(4891485)
 OTHER
Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis.
Kiso S, Naito R, Fukao K, Hiki M, Miyazaki T, Takagi A, Miyauchi K, Daida H.
Clin Case Rep. 2016;4(6):589-92.
Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis.
27398203
(4891485)
 OTHER
Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis.
Kiso S, Naito R, Fukao K, Hiki M, Miyazaki T, Takagi A, Miyauchi K, Daida H.
Clin Case Rep. 2016;4(6):589-92.
Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis.
27479013
 FEMALE
Thoracic Extramedullary Hematopoiesis Mimicking Metastatic Cancer.
Ha D, Liao X, Wang HY, Jamieson C, Magana M, Makani S.
J Bronchology Interv Pulmonol. 2016;23(4):343-346.
A bone marrow biopsy confirmed postpolycythemic myelofibrosis consistent with progression of polycythemia vera to myelofibrosis.
27479013
 FEMALE
Thoracic Extramedullary Hematopoiesis Mimicking Metastatic Cancer.
Ha D, Liao X, Wang HY, Jamieson C, Magana M, Makani S.
J Bronchology Interv Pulmonol. 2016;23(4):343-346.
A bone marrow biopsy confirmed postpolycythemic myelofibrosis consistent with progression of polycythemia vera to myelofibrosis.
25332522
 OTHER
A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.
Konca Degertekin C, Ozkurt ZN, Akyurek N, Yagc M.
Indian J Hematol Blood Transfus. 2014;30(Suppl 1):12-6.
Polycythemia vera is a clonal proliferative disorder of the bone marrow that could possibly evolve into myelofibrosis in its natural course.
24697128
 FEMALE Middle Aged
Polycythemia vera transforming to myelofibrosis and then biphenotype acute leukemia.
Dong XF, Yue LZ, Fu R, Shao ZH.
Clin Lab. 2014;60(3):495-9.
Polycythemia vera transforming to myelofibrosis and then biphenotype acute leukemia.
24697128
 FEMALE Middle Aged
Polycythemia vera transforming to myelofibrosis and then biphenotype acute leukemia.
Dong XF, Yue LZ, Fu R, Shao ZH.
Clin Lab. 2014;60(3):495-9.
A case with 17-year detailed illness history including evolution of polycythemia vera (PV) to myelofibrosis (MF) and then biphenotype acute leukemia (BAL) was reported.
24067929
 FEMALE Middle Aged
Reversible bone marrow aplasia induced by pegylated interferon-alpha-2a therapy in a patient with primary myelofibrosis.
Mainali NR, Bhatt VR, Kedia S, Krishnamurthy J, Wake LM, Akhtari M.
J Oncol Pharm Pract. 2014;20(5):386-92.
Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-945-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported.